Alnylam Pharmaceuticals Inc ALNY Phase 2 Diabetes Drug Progress and SP 500 Contender Status Lift Bullish Outlook ASX ASE Tech posts 148 percent Q4 2025 EPS beat but shares fall 389 percent in todays trading SILO Silo Pharma rises 557 percent despite reporting a wider than expected Q4 2023 per share loss VIASP Via quarterly earnings metrics not yet released market participants await key strategic updates from leadership Tesla Inc TSLA Solar Manufacturing Expansion and Grid Decarbonization Thesis Signal Undervalued Growth Lever